article Open AccessTop 1% cited

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Annals of Oncology · 2007 · Vol. 19(3) · pp. 508–515

Wendy De Roock(Center for Human Genetics)Hubert Piessevaux(Cliniques Universitaires Saint-Luc)Joris De Schutter(Center for Human Genetics)M. Janssens(Rode Kruis-Vlaanderen)Gert De Hertogh(KU Leuven)Nicola Personeni(KU Leuven)Bart Biesmans(Center for Human Genetics)Jean‐Luc Van Laethem(Université Libre de Bruxelles)Marc Peeters(Ghent University Hospital)Yves Humblet(Cliniques Universitaires Saint-Luc)Eric Van Cutsem(KU Leuven)Sabine Tejpar✉(Center for Human Genetics)

View via DOI Publisher page

Colorectal Cancer Treatments and Studies Hepatocellular Carcinoma Treatment and Prognosis Lung Cancer Treatments and MutationsKRASMedicineCetuximabColorectal cancerInternal medicineIrinotecanOncologyProportional hazards modelRefractory (planetary science)Cancer

MeSH terms

CetuximabIrinotecanAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleHumansMaleMiddle AgedMutationProto-Oncogene ProteinsRetrospective StudiesSensitivity and SpecificityTomography, X-Ray Computed

Citations

824

FWCI

47.73

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers